Sign up to save your podcasts
Or
Share Alzheimer’s Treatments, Dementia Early Detection, and the Future of Central Nervous System Research: Brad O’Connor
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Alzheimer’s Treatments, Dementia Early Detection, and the Future of Central Nervous System Research: Brad O’Connor
As life expectancy increases and survival rates for cancer and heart disease improve, central nervous system (CNS) conditions are increasingly becoming a focus in healthcare. The search to treat Alzheimer’s disease and other forms of dementia grows every day as more people feel their impact.
Cogstate CEO Brad O’Connor has over 20 years of experience driving his company to expand our collective knowledge and ability to detect CNS diseases as we work towards a cure for dementia. He and Medidata CEO Anthony Costello explore this critical and challenging area of clinical research, plus the strides being made to advance it.
Brad shares Cogstate’s work to develop new treatments and reliable, universal tests for assessing changes in cognition. From blood-based biomarkers to AI-powered clinical trials, Brad and Anthony outline a future for people with Alzheimer’s where earlier identification of risk factors leads to longer, happier lives for patients and loved ones.
Visit our website: www.medidata.com
Read our blog: Clinical Minds
Follow Medidata: LinkedIn, Instagram, X, YouTube
Follow Cogstate: LinkedIn, Instagram, X
Follow Anthony: LinkedIn
Follow Brad: LinkedIn
View all episodes
By MedidataAs life expectancy increases and survival rates for cancer and heart disease improve, central nervous system (CNS) conditions are increasingly becoming a focus in healthcare. The search to treat Alzheimer’s disease and other forms of dementia grows every day as more people feel their impact.
Cogstate CEO Brad O’Connor has over 20 years of experience driving his company to expand our collective knowledge and ability to detect CNS diseases as we work towards a cure for dementia. He and Medidata CEO Anthony Costello explore this critical and challenging area of clinical research, plus the strides being made to advance it.
Brad shares Cogstate’s work to develop new treatments and reliable, universal tests for assessing changes in cognition. From blood-based biomarkers to AI-powered clinical trials, Brad and Anthony outline a future for people with Alzheimer’s where earlier identification of risk factors leads to longer, happier lives for patients and loved ones.
Visit our website: www.medidata.com
Read our blog: Clinical Minds
Follow Medidata: LinkedIn, Instagram, X, YouTube
Follow Cogstate: LinkedIn, Instagram, X
Follow Anthony: LinkedIn
Follow Brad: LinkedIn